IMMUNEONCO-B (01541): IMM0306 Phase III Clinical Trial Application for Treatment of Follicular Lymphoma

Stock News
09/29

IMMUNEONCO-B (01541) announced that the Group has submitted an application for a Phase III clinical trial of IMM0306 to the Center for Drug Evaluation of China's National Medical Products Administration (NMPA).

IMM0306, independently developed by the Group, is a bispecific molecule targeting cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20), representing the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical stages.

IMM0306 works by inhibiting CD47-SIRPα interactions to block "don't eat me" signals, enhancing Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and NK cells, and preferentially binding to CD20 rather than CD47. This approach effectively eliminates malignant B cells while minimizing toxicity, thereby improving therapeutic outcomes.

As of the date of this announcement, the Group holds global intellectual property and commercialization rights for IMM0306.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10